PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

You may be eligible if

• Age ≥ 18 years at index date
• Diagnosis of mPC
• PSMA positive
• Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date
• Exclusion criterion:
• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)